Summary
Mutations of the tumour suppressor p53 gene are found in a number of spontaneous canine cancers and may contribute to increased cytogenetic alterations and tumour formation. Using reverse transcription and DNA amplification, we isolated p53 cDNA from normal and tumour tissue of ten canine mammary cancer patients. DNA sequencing identified p53 mutations in three of the ten patients. These included tumour-associated p53 gene mutations within exons 2 and 5 and a germ line deletion of exons 3 to 7. These results support a role for p53 inactivation in canine mammary tumour formation and breed predisposition to cancer. Such information could prove invaluable in the successful outbreeding of inherited predisposition to cancer in the dog. A putative polymorphism was also identified at codon 69 in exon 4 and we discuss the possibility that similar polymorphisms may be associated with human breast cancer.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ara, S, Lee, PS, Hansen, MF & Saya, H (1990). Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 18: 4961.
Berns, EM, Klijn, JG, Smid, M, van Staveren, IL, Look, MP, van Putten, WL & Foekens, JA (1996). TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients. Genes Chromosomes Cancer 16: 170–179.
Béroud, C & Soussi, T (1998). p53 gene mutation: software and database. Nucleic Acids Res 26: 200–204.
Birch, JM, Blair, V, Kelsey, AM, Evans, DG, Harris, M, Tricker, KJ & Varley, JM (1998). Cancer phenotype correlates with constitutional TP53 genotype in families with the Li–Fraumeni syndrome. Oncogene 17: 1061–1068.
Casey, G, Lopez, ME, Ramos, JC, Plummer, SJ, Arboleda, MJ, Shaughnessy, M, Karlan, B & Slamon, DJ (1996). DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 13: 1971–1981.
Chang, H, Benchimol, S, Minden, MD & Messner, HA (1994). Alterations of p53 and c-myc in the clonal evolution of malignant lymphoma. Blood 83: 452–459.
Chu, LL, Rutteman, GR, Kong, JMC, Ghahremani, M, Schmeing, M, Misdorp, W, van Garderen, E & Pelletier, J (1998). Genomic organization of the canine p53 gene and its mutational status in canine mammary neoplasia. Breast Cancer Res Treat 50: 11–25.
Cook, A & Milner, J (1990). Evidence for allosteric variants of wild-type p53, a tumour suppressor protein. Br J Cancer 61: 548–552.
Devilee, P, van Leeuwen, IS, Voesten, A, Rutteman, GR, Vos, JH & Cornelisse, CJ (1994). The canine p53 gene is subject to somatic mutations in thyroid carcinoma. Anticancer Res 14: 2039–2046.
Faille, A, De Cremoux, P, Extra, JM, Linares, G, Espie, M, Bourstyn, E, De Rocquancourt, A, Giacchetti, S, Marty, M & Calvo, F (1994). p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer 69: 1145–1150.
Gamble, J & Milner, J (1988). Evidence that immunological variants of p53 represent alternative protein conformations. Virology 162: 452–458.
Gannon, JV, Greaves, R, Iggo, R & Lane, DP (1990). Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9: 1595–1602.
Glebov, OK, McKenzie, KE, White, CA & Sukumar, S (1994). Frequent p53 gene mutations and novel alleles in familial breast cancer. Cancer Res 54: 3703–3709.
Hainaut, P, Soussi, T, Shomer, B, Hollstein, M, Greenblatt, M, Hovig, E, Harris, CC & Montesano, R (1997). Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res 25: 151–157.
Hartmann, A, Blaszyk, H, Kovach, JS & Sommer, SS (1997). The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet 13: 27–33.
Helland, Å, Langerød, A, Johnsen, H, Olsen, AO, Skovlund, E & Børresen-Dale, A-L (1998). p53 polymorphism and risk of cervical cancer. Nature 396: 530–531.
Hirano, Y, Yamato, K & Tsuchida, N (1995). A temperature sensitive mutant of the human p53, Val138, arrests rat cell growth without induced expression of cip1/waf1/sdi1 after temperature shift-down. Oncogene 10: 1879–1885.
Huang, Y, Yin, J & Meltzer, SJ (1994). A unique p53 intragenic deletion flanked by short direct repeats results in loss of mRNA expression in a human esophageal carcinoma. Carcinogenesis 15: 1653–1655.
Johnson, AS, Couto, CG & Weghorst, CM (1998). Mutation of the p53 tumor suppressor gene in spontaneously occurring osteosarcomas of the dog. Carcinogenesis 19: 213–217.
Kussie, PH, Gorina, S, Marechal, V, Elenbaas, B, Moreau, J, Levine, AJ & Pavletich, N (1996). Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948–953.
Lin, J, Wu, X, Chen, J, Chang, A & Levine, AJ (1995). Functions of the p53 protein in growth-regulation and tumor suppression. Cold Spring Harbor Symp Quant Biol 59: 215–223.
MacVean, DW, Monlux, AW, Anderson, PS Jr, Silberg, SL & Roszel, JF (1978). Frequency of canine and feline tumors in a defined population. Vet Pathol 15: 700–715.
Malkin, D (1994). Germline p53 mutations and heritable cancer. Annu Rev Genet 28: 443–465.
Martinez, J, Georgoff, I, Martinez, J & Levine, A (1991). Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev 5: 151–159.
Mayr, B, Schellander, K, Schleger, W & Reifinger, M (1994). Sequence of an exon of the canine p53 gene-mutation in a papilloma. Br Vet J 150: 81–84.
Mayr, B, Schaffner, W, Botto, I, Reifinger, M & Loupal, G (1997). Canine tumour suppressor gene p53-mutation in a case of adenoma of circumanal glands. Vet Res Comm 21: 369–373.
Mayr, B, Dressler, A, Reifinger, M & Feil, C (1998). Cytogenetic alterations in eight mammary tumors and tumor-suppressor gene p53 mutation in one mammary tumor from dogs. Am J Vet Res 59: 69–78.
Minaguchi, T, Kanamori, Y, Matsushima, M, Yoshikawa, H, Taketani, Y & Nakamura, Y (1998). No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection. Cancer Res 58: 4585–4586.
Moll, UM, Riou, G & Levine, AJ (1992). Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 89: 7262–7266.
Priester, WA & McKay, FW (1980). The occurrence of tumors in domestic animals. Natl Cancer Inst Monograph 54: 152–184.
Rolley, N, Butcher, S & Milner, J (1995). Specific DNA binding by different classes of human p53 mutants. Oncogene 11: 763–770.
Rosenthal, AN, Ryan, A, Al-Jehani, RM, Storey, A, Harwood, CA & Jacobs, IJ (1998). p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 352: 871–872.
Seth, A, Palli, D, Mariano, JM, Metcalf, R, Venanzoni, M, Bianchi, S, Kottaridis, SD & Papas, TS (1994). P53 gene mutations in women with breast cancer and a previous history of benign breast disease. Eur J Cancer 30A: 808–812.
Storey, A, Thomas, M, Kalita, A, Harwood, C, Gardiol, D, Mantovani, F, Breuer, J, Leigh, IM, Matlashewski, G & Banks, L (1998). Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393: 229–234.
Strauss, BS (1997). Silent and multiple mutations in p53 and the question of the hypermutability of tumors. Carcinogenesis 18: 1445–1452.
Sun, X-F, Johannsson, O, Håkansson, S, Sellberg, G, Nordenskjöld, B, Olsson, H & Borg, A (1996). A novel p53 germline alteration identified in a late onset breast cancer kindred. Oncogene 13: 407–411.
Tagawa, M, Murata, M & Kimura, H (1998). Prognostic value of mutations and germ line polymorphism of the p53 gene in non-small cell lung carcinoma: association with clinicopathological features. Cancer Lett 128: 93–99.
Tornaletti, S & Pfeifer, GP (1995). Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers. Oncogene 10: 1493–1499.
van Leeuwen, IS, Hellmen, E, Cornelisse, CJ, van den Burgh, B & Rutteman, GR (1996). P53 mutations in mammary tumor cell lines and corresponding tumor tissues in the dog. Anticancer Res 16: 3737–3744.
van Leeuwen, IS, Cornelisse, CJ, Misdorp, W, Goedegebuure, SA, Kirpensteijn, J & Rutteman, GR (1997). P53 gene mutations in osteosarcomas in the dog. Cancer Lett 111: 173–178.
Veldhoen, N & Milner, J (1998). Isolation of canine p53 cDNA and detailed characterization of the full length canine p53 protein. Oncogene 16: 1077–1084.
Veldhoen, N, Stewart, J, Brown, R & Milner, J (1998). Mutations of the p53 gene in canine lymphoma and evidence for germ line p53 mutations in the dog. Oncogene 16: 249–255.
Venkatachalam, S, Shi, Y-P, Jones, SN, Vogel, H, Bradley, A, Pinkel, D & Donehower, LA (1998). Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 17: 4657–4667.
Wada, H, Asada, M, Nakazawa, S, Itoh, H, Kobayashi, Y, Inoue, T, Fukumuro, K, Chan, LC, Sugita, K, Hanada, R, Akuta, N, Kobayashi, N & Mizutani, S (1994). Clonal expansion of p53 mutant cells in leukemia progression in vitro. Leukemia 8: 53–59.
Yamato, K, Yamamoto, M, Hirano, Y & Tsuchida, N (1995). A human temperature-sensitive p53 mutant p53val-138: modulation of the cell cycle, viability and expression of p53-responsive genes. Oncogene 11: 1–6.
Author information
Authors and Affiliations
Additional information
Correspondence to: J Milner
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Veldhoen, N., Watterson, J., Brash, M. et al. Identification of tumour-associated and germ line p53 mutations in canine mammary cancer. Br J Cancer 81, 409–415 (1999). https://doi.org/10.1038/sj.bjc.6690709
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690709
Keywords
This article is cited by
-
Establishment of TP53-knockout canine cells using optimized CRIPSR/Cas9 vector system for canine cancer research
BMC Biotechnology (2019)
-
The ESR1 gene is associated with risk for canine mammary tumours
BMC Veterinary Research (2013)
